MGMT promoter methylation status is prognostic in IDH1/2wt glioblastoma

MGMT promoter methylation may be prognostic in patients with IDH1/2wt anaplastic glioma, according to an analysis of data from a phase 3 trial conducted by the European Organization for the Treatment of Cancer (EORTC).

Dr Mircea Tesileanu of the Erasmus MC Cancer Institute in Rotterdam, Netherlands, presented the findings at SNO 2020. The trial, known as CATNON, compared radiation therapy plus temozolomide to radiation therapy alone in patients with newly diagnosed 1p/19q non-codeleted anaplastic glioma.

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.